ALL
Pharma in China
Pharma Experts
Market News
Products Guide
Brand Story
-
Merck's Steglatro shows limited promise with heart failure hospitalization data
September 01, 2020Late to the party against its SGLT2 diabetes rivals, Merck & Co.'s Steglatro has also tracked way behind in the class' growing presence in heart failure. -
MSD/Pfizer's diabetes drug Steglatro hits goal in CV outcomes trial
June 22, 2020MSD and Pfizer have unveiled data from the Phase III VERTIS CV cardiovascular (CV) outcomes trial which add further evidence on the safety of their diabetes drug Steglatro (ertugliflozin). -
Merck and Pfizer’s SGLT2 inhibitor STEGLATRO meets primary endpoint in VERTIS CV trial
June 18, 2020Merck, known as MSD outside the United States and Canada, and Pfizer Inc., announced the presentation of results from the Phase 3 VERTIS CV cardiovascular (CV) outcomes trial that evaluated STEGLATRO (ertugliflozin) ...
Pharma Sources Insight January 2025
